TriangleNCT02567422 · OUTCOME
Establish the Recommended Phase 2 Dose (RP2D)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- mg/m^2
- Interval / dispersion
- Not reported
- Time frame
- Up to 7 weeks
What was measured
Defined as the highest doses of cisplatin and berzosertib safely combined with radiation.
Groups in this outcome
Dose Escalation
Patients received different doses of M6620 (VX-970, berzosertib) by infusion in their arm weekly, cisplatin 40 mg/m2 IV weekly starting a week after M6620, and radiation therapy 70 Gy daily Monday-Friday also starting a week after M6620.
| Group | Source count |
|---|---|
| Dose Escalation | 28 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Dose Escalation | 200 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 200
- denoms
- counts
- group Id
- OG000
- value
- 28
- units
- Participants
- description
- Defined as the highest doses of cisplatin and berzosertib safely combined with radiation.
- groups
- description
- Patients received different doses of M6620 (VX-970, berzosertib) by infusion in their arm weekly, cisplatin 40 mg/m2 IV weekly starting a week after M6620, and radiation therapy 70 Gy daily Monday-Friday also starting a week after M6620.
- id
- OG000
- title
- Dose Escalation
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- Up to 7 weeks
- title
- Establish the Recommended Phase 2 Dose (RP2D)
- type
- PRIMARY
- unit Of Measure
- mg/m^2
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice